LinkedIn · Nov 2024
Company post announcing the NSF SBIR Phase I grant and its focus on conditionally active protein medicines.
"If-then" conditional logic for protein drugs
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Biotechnology research startup founded in 2023, building conditional "if-then" protein therapeutics that activate only at diseased tissue and aim to improve the safety of cancer immunotherapies. Founders are brothers Elliot and Nathan Tague; the company was in Y Combinator Winter 2024. Public sources conflict slightly on HQ and funding totals (Cambridge vs. Somerville; roughly $500K-$625K reported), and I did not find a separate public CEO listing, careers page, GitHub, X, or engineering blog.
Primary product
Conditionally activated protein therapeutics ('if-then' gated protein medicines) for localized disease treatment
Founded
2023
Headquarters
Cambridge, Massachusetts, United States
Team size
1-10 employees
Industry
Biotechnology Research
Sub-industry
Protein therapeutics / drug discovery
Offices
Cambridge, Massachusetts, United States
Somerville, Massachusetts, United States
Business model
therapeutic platform
drug discovery
Funding
Stage
pre-seed
Total raised
$625K
Latest round
NSF SBIR Phase I grant · Jul 2024
Latest amount
$275K
Jul 2024 · US National Science Foundation
Apr 2024 · Y Combinator
Mar 2024
Sep 2023
People & investors
Work & culture
Product & market
Differentiators
- —"If-then" conditional logic activates protein medicines only when a disease marker is sensed
- —Designed to localize activity to diseased tissue and reduce systemic toxicity
- —Flexible platform intended to be adaptable across many biomolecules and disease areas
Technology
synthetic biology
protein engineering
conditional protein therapeutics
disease-marker sensing
protein degradation / optogenetics research
Scale & contact
Latest news
SBIR.gov · Jul 2024
NSF SBIR Phase I award of $275K for disease-activated cancer immunotherapy work.
HireTop · Jun 2024
Profile article describing SynsoryBio's disease-sensing protein therapeutics platform and market focus.
Startup Intros · Apr 2024
Startup Intros reports a $500K seed-stage round for SynsoryBio.
Y Combinator · Feb 2024
YC launch introducing SynsoryBio's conditional protein therapeutics platform and founders.
Jobs and careers at SynsoryBio
0 jobs at SynsoryBio
No open positions
Check back later for new openings